Structure and functionality of a designed p53 dimer

P53 is a homotetrameric tumor suppressor protein involved in transcriptional control of genes that regulate cell proliferation and death. In order to probe the role that oligomerization plays in this capacity, we have previously designed and characterized a series of p53 proteins with altered oligom...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of molecular biology 2001-03, Vol.307 (2), p.605-617
Hauptverfasser: Davison, Timothy S, Nie, X, Ma, Weili, Lin, Yunping, Kay, C, Benchimol, S, Arrowsmith, Cheryl H
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 617
container_issue 2
container_start_page 605
container_title Journal of molecular biology
container_volume 307
creator Davison, Timothy S
Nie, X
Ma, Weili
Lin, Yunping
Kay, C
Benchimol, S
Arrowsmith, Cheryl H
description P53 is a homotetrameric tumor suppressor protein involved in transcriptional control of genes that regulate cell proliferation and death. In order to probe the role that oligomerization plays in this capacity, we have previously designed and characterized a series of p53 proteins with altered oligomeric states through hydrophilc substitution of residues Met340 or Leu344 in the normally tetrameric oligomerization domain. Although such mutations have little effect on the overall secondary structural content of the oligomerization domain, both solubility and the resistance to thermal denaturation are substantially reduced relative to that of the wild-type domain. Here, we report the design and characterization of a double-mutant p53 with alterations of residues at positions Met340 and Leu344. The double-mutations Met340Glu/Leu344Lys and Met340Gln/Leu344Arg resulted in distinct dimeric forms of the protein. Furthermore, we have verified by NMR structure determination that the double-mutant Met340Gln/Leu344Arg is essentially a “half-tetramer”. Analysis of the in vivo activities of full-length p53 oligomeric mutants reveals that while cell-cycle arrest requires tetrameric p53, transcriptional transactivation activity of monomers and dimers retain roughly background and half of the wild-type activity, respectively.
doi_str_mv 10.1006/jmbi.2001.4450
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_17848186</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S002228360194450X</els_id><sourcerecordid>17848186</sourcerecordid><originalsourceid>FETCH-LOGICAL-e287t-7ec0e68e06e58358deefe19de560a13d19174e466b8e2fe5f8354482d6de411e3</originalsourceid><addsrcrecordid>eNo1kEtLw0AUhQdRbK1uXUpW7lLvPHO7lOILCi7U9ZBmbmRKHnVmIvTfm9C6OpuPwzkfY7cclhzAPOzarV8KAL5USsMZm3PAVY5G4jmbAwiRC5Rmxq5i3AGAlgov2YxzoZVEPWfyI4WhSkOgrOxcVg9dlXzflY1Ph6yvszJzFP13Ry7ba5k531K4Zhd12US6OeWCfT0_fa5f8837y9v6cZOTwCLlBVVABgkMaZQaHVFNfOVIGyi5dHzFC0XKmC2SqEnXI6QUCmccKc5JLtj9sXcf-p-BYrKtjxU1TdlRP0TLC1TIx68LdncCh21Lzu6Db8twsP83RwCPAI1zfz0FGytPXUXOB6qSdb23HOxk1E5G7WTUTkblH-S7Zkg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17848186</pqid></control><display><type>article</type><title>Structure and functionality of a designed p53 dimer</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Davison, Timothy S ; Nie, X ; Ma, Weili ; Lin, Yunping ; Kay, C ; Benchimol, S ; Arrowsmith, Cheryl H</creator><creatorcontrib>Davison, Timothy S ; Nie, X ; Ma, Weili ; Lin, Yunping ; Kay, C ; Benchimol, S ; Arrowsmith, Cheryl H</creatorcontrib><description>P53 is a homotetrameric tumor suppressor protein involved in transcriptional control of genes that regulate cell proliferation and death. In order to probe the role that oligomerization plays in this capacity, we have previously designed and characterized a series of p53 proteins with altered oligomeric states through hydrophilc substitution of residues Met340 or Leu344 in the normally tetrameric oligomerization domain. Although such mutations have little effect on the overall secondary structural content of the oligomerization domain, both solubility and the resistance to thermal denaturation are substantially reduced relative to that of the wild-type domain. Here, we report the design and characterization of a double-mutant p53 with alterations of residues at positions Met340 and Leu344. The double-mutations Met340Glu/Leu344Lys and Met340Gln/Leu344Arg resulted in distinct dimeric forms of the protein. Furthermore, we have verified by NMR structure determination that the double-mutant Met340Gln/Leu344Arg is essentially a “half-tetramer”. Analysis of the in vivo activities of full-length p53 oligomeric mutants reveals that while cell-cycle arrest requires tetrameric p53, transcriptional transactivation activity of monomers and dimers retain roughly background and half of the wild-type activity, respectively.</description><identifier>ISSN: 0022-2836</identifier><identifier>EISSN: 1089-8638</identifier><identifier>DOI: 10.1006/jmbi.2001.4450</identifier><identifier>PMID: 11254385</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Binding Sites ; Cell Cycle ; cell cycle arrest ; Circular Dichroism ; Computer Simulation ; Dimerization ; Humans ; Models, Molecular ; Mutagenesis, Site-Directed ; Mutation ; NMR ; Nuclear Magnetic Resonance, Biomolecular ; oligomerization ; p53 dimer ; Peptide Fragments ; Protein Binding ; Protein Engineering ; Protein Structure, Quaternary ; Recombinant Proteins - chemistry ; Recombinant Proteins - metabolism ; Thermodynamics ; Transcriptional Activation ; transcriptional transactivation ; Tumor Suppressor Protein p53 - chemistry ; Tumor Suppressor Protein p53 - genetics ; Tumor Suppressor Protein p53 - metabolism</subject><ispartof>Journal of molecular biology, 2001-03, Vol.307 (2), p.605-617</ispartof><rights>2001 Academic Press</rights><rights>Copyright 2001 Academic Press.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S002228360194450X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11254385$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Davison, Timothy S</creatorcontrib><creatorcontrib>Nie, X</creatorcontrib><creatorcontrib>Ma, Weili</creatorcontrib><creatorcontrib>Lin, Yunping</creatorcontrib><creatorcontrib>Kay, C</creatorcontrib><creatorcontrib>Benchimol, S</creatorcontrib><creatorcontrib>Arrowsmith, Cheryl H</creatorcontrib><title>Structure and functionality of a designed p53 dimer</title><title>Journal of molecular biology</title><addtitle>J Mol Biol</addtitle><description>P53 is a homotetrameric tumor suppressor protein involved in transcriptional control of genes that regulate cell proliferation and death. In order to probe the role that oligomerization plays in this capacity, we have previously designed and characterized a series of p53 proteins with altered oligomeric states through hydrophilc substitution of residues Met340 or Leu344 in the normally tetrameric oligomerization domain. Although such mutations have little effect on the overall secondary structural content of the oligomerization domain, both solubility and the resistance to thermal denaturation are substantially reduced relative to that of the wild-type domain. Here, we report the design and characterization of a double-mutant p53 with alterations of residues at positions Met340 and Leu344. The double-mutations Met340Glu/Leu344Lys and Met340Gln/Leu344Arg resulted in distinct dimeric forms of the protein. Furthermore, we have verified by NMR structure determination that the double-mutant Met340Gln/Leu344Arg is essentially a “half-tetramer”. Analysis of the in vivo activities of full-length p53 oligomeric mutants reveals that while cell-cycle arrest requires tetrameric p53, transcriptional transactivation activity of monomers and dimers retain roughly background and half of the wild-type activity, respectively.</description><subject>Binding Sites</subject><subject>Cell Cycle</subject><subject>cell cycle arrest</subject><subject>Circular Dichroism</subject><subject>Computer Simulation</subject><subject>Dimerization</subject><subject>Humans</subject><subject>Models, Molecular</subject><subject>Mutagenesis, Site-Directed</subject><subject>Mutation</subject><subject>NMR</subject><subject>Nuclear Magnetic Resonance, Biomolecular</subject><subject>oligomerization</subject><subject>p53 dimer</subject><subject>Peptide Fragments</subject><subject>Protein Binding</subject><subject>Protein Engineering</subject><subject>Protein Structure, Quaternary</subject><subject>Recombinant Proteins - chemistry</subject><subject>Recombinant Proteins - metabolism</subject><subject>Thermodynamics</subject><subject>Transcriptional Activation</subject><subject>transcriptional transactivation</subject><subject>Tumor Suppressor Protein p53 - chemistry</subject><subject>Tumor Suppressor Protein p53 - genetics</subject><subject>Tumor Suppressor Protein p53 - metabolism</subject><issn>0022-2836</issn><issn>1089-8638</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kEtLw0AUhQdRbK1uXUpW7lLvPHO7lOILCi7U9ZBmbmRKHnVmIvTfm9C6OpuPwzkfY7cclhzAPOzarV8KAL5USsMZm3PAVY5G4jmbAwiRC5Rmxq5i3AGAlgov2YxzoZVEPWfyI4WhSkOgrOxcVg9dlXzflY1Ph6yvszJzFP13Ry7ba5k531K4Zhd12US6OeWCfT0_fa5f8837y9v6cZOTwCLlBVVABgkMaZQaHVFNfOVIGyi5dHzFC0XKmC2SqEnXI6QUCmccKc5JLtj9sXcf-p-BYrKtjxU1TdlRP0TLC1TIx68LdncCh21Lzu6Db8twsP83RwCPAI1zfz0FGytPXUXOB6qSdb23HOxk1E5G7WTUTkblH-S7Zkg</recordid><startdate>20010323</startdate><enddate>20010323</enddate><creator>Davison, Timothy S</creator><creator>Nie, X</creator><creator>Ma, Weili</creator><creator>Lin, Yunping</creator><creator>Kay, C</creator><creator>Benchimol, S</creator><creator>Arrowsmith, Cheryl H</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7TM</scope><scope>7TO</scope><scope>H94</scope></search><sort><creationdate>20010323</creationdate><title>Structure and functionality of a designed p53 dimer</title><author>Davison, Timothy S ; Nie, X ; Ma, Weili ; Lin, Yunping ; Kay, C ; Benchimol, S ; Arrowsmith, Cheryl H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e287t-7ec0e68e06e58358deefe19de560a13d19174e466b8e2fe5f8354482d6de411e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Binding Sites</topic><topic>Cell Cycle</topic><topic>cell cycle arrest</topic><topic>Circular Dichroism</topic><topic>Computer Simulation</topic><topic>Dimerization</topic><topic>Humans</topic><topic>Models, Molecular</topic><topic>Mutagenesis, Site-Directed</topic><topic>Mutation</topic><topic>NMR</topic><topic>Nuclear Magnetic Resonance, Biomolecular</topic><topic>oligomerization</topic><topic>p53 dimer</topic><topic>Peptide Fragments</topic><topic>Protein Binding</topic><topic>Protein Engineering</topic><topic>Protein Structure, Quaternary</topic><topic>Recombinant Proteins - chemistry</topic><topic>Recombinant Proteins - metabolism</topic><topic>Thermodynamics</topic><topic>Transcriptional Activation</topic><topic>transcriptional transactivation</topic><topic>Tumor Suppressor Protein p53 - chemistry</topic><topic>Tumor Suppressor Protein p53 - genetics</topic><topic>Tumor Suppressor Protein p53 - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Davison, Timothy S</creatorcontrib><creatorcontrib>Nie, X</creatorcontrib><creatorcontrib>Ma, Weili</creatorcontrib><creatorcontrib>Lin, Yunping</creatorcontrib><creatorcontrib>Kay, C</creatorcontrib><creatorcontrib>Benchimol, S</creatorcontrib><creatorcontrib>Arrowsmith, Cheryl H</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Journal of molecular biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Davison, Timothy S</au><au>Nie, X</au><au>Ma, Weili</au><au>Lin, Yunping</au><au>Kay, C</au><au>Benchimol, S</au><au>Arrowsmith, Cheryl H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Structure and functionality of a designed p53 dimer</atitle><jtitle>Journal of molecular biology</jtitle><addtitle>J Mol Biol</addtitle><date>2001-03-23</date><risdate>2001</risdate><volume>307</volume><issue>2</issue><spage>605</spage><epage>617</epage><pages>605-617</pages><issn>0022-2836</issn><eissn>1089-8638</eissn><abstract>P53 is a homotetrameric tumor suppressor protein involved in transcriptional control of genes that regulate cell proliferation and death. In order to probe the role that oligomerization plays in this capacity, we have previously designed and characterized a series of p53 proteins with altered oligomeric states through hydrophilc substitution of residues Met340 or Leu344 in the normally tetrameric oligomerization domain. Although such mutations have little effect on the overall secondary structural content of the oligomerization domain, both solubility and the resistance to thermal denaturation are substantially reduced relative to that of the wild-type domain. Here, we report the design and characterization of a double-mutant p53 with alterations of residues at positions Met340 and Leu344. The double-mutations Met340Glu/Leu344Lys and Met340Gln/Leu344Arg resulted in distinct dimeric forms of the protein. Furthermore, we have verified by NMR structure determination that the double-mutant Met340Gln/Leu344Arg is essentially a “half-tetramer”. Analysis of the in vivo activities of full-length p53 oligomeric mutants reveals that while cell-cycle arrest requires tetrameric p53, transcriptional transactivation activity of monomers and dimers retain roughly background and half of the wild-type activity, respectively.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>11254385</pmid><doi>10.1006/jmbi.2001.4450</doi><tpages>13</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-2836
ispartof Journal of molecular biology, 2001-03, Vol.307 (2), p.605-617
issn 0022-2836
1089-8638
language eng
recordid cdi_proquest_miscellaneous_17848186
source MEDLINE; Elsevier ScienceDirect Journals
subjects Binding Sites
Cell Cycle
cell cycle arrest
Circular Dichroism
Computer Simulation
Dimerization
Humans
Models, Molecular
Mutagenesis, Site-Directed
Mutation
NMR
Nuclear Magnetic Resonance, Biomolecular
oligomerization
p53 dimer
Peptide Fragments
Protein Binding
Protein Engineering
Protein Structure, Quaternary
Recombinant Proteins - chemistry
Recombinant Proteins - metabolism
Thermodynamics
Transcriptional Activation
transcriptional transactivation
Tumor Suppressor Protein p53 - chemistry
Tumor Suppressor Protein p53 - genetics
Tumor Suppressor Protein p53 - metabolism
title Structure and functionality of a designed p53 dimer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T19%3A38%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Structure%20and%20functionality%20of%20a%20designed%20p53%20dimer&rft.jtitle=Journal%20of%20molecular%20biology&rft.au=Davison,%20Timothy%20S&rft.date=2001-03-23&rft.volume=307&rft.issue=2&rft.spage=605&rft.epage=617&rft.pages=605-617&rft.issn=0022-2836&rft.eissn=1089-8638&rft_id=info:doi/10.1006/jmbi.2001.4450&rft_dat=%3Cproquest_pubme%3E17848186%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17848186&rft_id=info:pmid/11254385&rft_els_id=S002228360194450X&rfr_iscdi=true